Abstract | OBJECTIVE: Treatment of Crohn's disease (CD) with anti- tumor necrosis factor α (TNFα) decreases intestinal inflammation, but the effect on fibrosis remains unclear. We hypothesized that treatment with rat-specific anti-TNFα will decrease the development of intestinal fibrosis in a rat model of CD. We further hypothesized that magnetization transfer magnetic resonance imaging (MT-MRI) will be sensitive in detecting these differences in collagen content. METHODS: RESULTS: PG-PS-injected rats treated with anti-TNFα had less histologic inflammation, and cecal tissue expressed lower levels of proinflammatory cytokine messenger RNAs than vehicle-treated PG-PS-injected rats (IL-1β: 5.59 ± 1.53 versus 10.41 ± 1.78, P = 0.02; IL-6: 23.23 ± 9.33 versus 45.89 ± 11.79, P = 0.07). PG-PS-injected rats treated with anti-TNFα developed less intestinal fibrosis than vehicle-treated PG-PS-injected rats by tissue procollagen I (2.87 ± 0.66 versus 9.28 ± 1.11; P = 0.00002), procollagen III (2.25 ± 0.35 versus 7.28 ± 0.76; P = 0.0000009), and MT-MRI (MT ratio: 17.79 ± 1.61 versus 27.95 ± 1.75; P = 0.0001). Insulin-like growth factor I (2.52 ± 0.44 versus 5.14 ± 0.60; P = 0.0007) and transforming growth factor β1 (2.34 ± 0.29 versus 3.45 ± 0.29; P = 0.006) were also decreased in anti-TNFα-treated PG-PS-injected rats. CONCLUSIONS: Anti-TNFα prevents the development of bowel wall inflammation and fibrosis in the PG-PS rat model of CD. MT-MRI measurably demonstrates this decrease in intestinal fibrosis.
|
Authors | Jeremy Adler, Kinan Rahal, Scott D Swanson, Phyllissa Schmiedlin-Ren, Ahren C Rittershaus, Laura J Reingold, Josh S Brudi, David Shealy, Ann Cai, Barbara J McKenna, Ellen M Zimmermann |
Journal | Inflammatory bowel diseases
(Inflamm Bowel Dis)
2013 Mar-Apr
Vol. 19
Issue 4
Pg. 683-90
ISSN: 1536-4844 [Electronic] England |
PMID | 23429466
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Inflammatory Agents
- Cytokines
- Peptidoglycan
- Procollagen
- RNA, Messenger
- Serum Albumin
- Tumor Necrosis Factor-alpha
- Insulin-Like Growth Factor I
|
Topics |
- Animals
- Anti-Inflammatory Agents
(therapeutic use)
- Colitis
(chemically induced, pathology, prevention & control)
- Crohn Disease
(chemically induced, pathology, prevention & control)
- Cytokines
(genetics)
- Disease Models, Animal
- Female
- Fibrosis
(chemically induced, pathology, prevention & control)
- Humans
- Inflammation
(chemically induced, pathology, prevention & control)
- Insulin-Like Growth Factor I
(genetics)
- Intestinal Diseases
(chemically induced, pathology, prevention & control)
- Magnetic Resonance Imaging
- Magnetics
- Peptidoglycan
(toxicity)
- Procollagen
(genetics)
- RNA, Messenger
(genetics)
- Rats
- Rats, Inbred Lew
- Real-Time Polymerase Chain Reaction
- Serum Albumin
(toxicity)
- Tumor Necrosis Factor-alpha
(antagonists & inhibitors)
|